Drug Profile
Research programme: cancer therapeutics - Kineta Immuno Oncology
Alternative Names: KIN 131A; RIG-I agonist - Kineta Immuno Oncology; RIG-I like receptor - Kineta; RLR Agonist - KinetaLatest Information Update: 28 Apr 2021
Price :
$50
*
At a glance
- Originator Kineta
- Class Antineoplastics; Small molecules
- Mechanism of Action DDX58 protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Apr 2021 No recent reports of development identified for preclinical development in Cancer in USA
- 17 Dec 2018 Kineta Immuno-Oncology and Pfizer collaborates to co-develop RIG-I like receptor agonist for Cancer
- 05 Apr 2018 Pharmacodynamics data from a preclinical study in Cancer released by Kineta